Gilead and Teva Pharmaceuticals, two top big pharma companies, have reached a settlement agreement in principle to settle the ongoing patent litigation concerning the patents protecting Viread (tenofovir disoproxil fumarate).

Viread (tenofovir disoproxil fumarate), a treatment for HIV infection and chronic hepatitis B.

Under the terms of the settlement agreement, Teva will be allowed to launch a generic version of Viread on December 15, 2017.

The trial in this settlement agreement, which was scheduled to begin on Wednesday, February 20 in the District Court for the Southern District of New York, has been adjourned pending completion of activities necessary to finalize the settlement agreement.

For further deal information visit Current Agreements (subscription required)

Related

Read: more on Teva :company profile, recent partnering, M&A and financing news and articles

Read: more on Gilead :company profile, recent partnering, M&A and financing news and articles

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Report: Partnering Agreements with Big Pharma ; Partnering Agreements with Teva 2005-2013 ; Partnering Agreements with Gilead Sciences 2005-2013

View also: Top 50 Bigpharma list

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now